DDInter94 DDInter255
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Altretamine
Altretamine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Altretamine
Altretamine {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) GPER1
GPER1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) CCNB1
CCNB1 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) is upregulated by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) upregulates DECR1 (Gene) and DECR1 (Gene) is downregulated by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates CCNB1 (Gene) and CCNB1 (Gene) is downregulated by Busulfan (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) binds EPHA3 (Gene) and Nilotinib (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is upregulated by Busulfan (Compound)